| 证券代码 | ARNA.O |
| 证券名称 | Arena Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2000-07-28 |
| 首发价格(元) | 18 USD |
| 首发数量(股) | 6000000 |
| 首发募资额(元) | 108,000,000.00 USD |
| 首发主承销商 | ING Barings LLC,Prudential Securities Incorporated,SG Cowen Secu |
| 货币单位 | USD |
| 公司名称 | Arena Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 6154 Nancy Ridge Drive, San Diego, California, USA |
| 成立日期 | 1997-04-14 |
| 董事会主席 | Garry A. Neil |
| 公司属地 | United States 美国 |
| 公司网址 | www.arenapharm.com |
| 电话 | +1 (858) 453-7200 |
| 传真 | - |
| 公司简介 | Arena Pharmaceuticals, Inc. is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. The most advanced investigational clinical programs are ralinepag (APD811), in a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), expected to commence a Phase 3 program for ulcerative colitis (UC) and a program in Crohn’s Disease (CD), and which has potential utility for a broad range of immune and inflammatory conditions. Arena is also evaluating olorinab (APD371) in a Phase 2 study for the treatment of visceral pain associated with Crohn's disease, as well as other drug candidates in earlier research and development stages. |